ERCC1 and breast cancer: Along these lines, specific ERCC1 polymorphisms have been shown to associate with increased BC susceptibility [33], and high ERCC1 protein expression in the primary tissue has been shown to associate with poor outcomes in metastatic triple negative BC patients treated with platinum-based chemotherapy [34].